Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats

被引:7
作者
Qiang, Fu [1 ]
Lee, Beom-Jin [2 ]
Lee, Wonjae [1 ]
Han, Hyo-Kyung [1 ]
机构
[1] Chosun Univ, Coll Pharm, BK21 Project Team, Kwangju 501752, South Korea
[2] Kangwon Natl Univ, Coll Pharm, Bioavailabil Control Lab, Chunchon 200701, South Korea
关键词
Fexofenadine; Fluvastatin; Organic anion-transporting polypeptides; Drug interaction; Rat; COA REDUCTASE INHIBITORS; CLINICAL PHARMACOKINETICS; FRUIT JUICES; OATP; DISPOSITION; HUMANS; BIOAVAILABILITY; LEVOCETIRIZINE; DESLORATADINE; LOVASTATIN;
D O I
10.1016/j.ejps.2009.03.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study aimed to examine the transporter-mediated drug interaction between fexofenadine and fluvastatin in rats. Compared to the control group given fluvastatin alone, the concurrent use of fexofenadine (10 or 20 mg/kg) prior to the oral administration of fluvastatin (5 mg/kg) decreased the systemic exposure of fluvastatin by 17-51% in rats. Consequently, the bioavailability of oral fluvastatin was significantly lower(p < 0.05) in the presence of fexofenadine compared to that from the control group. Furthermore, the intravenous pharmacokinetics of fluvastatin (2 mg/kg) was significantly altered by the pretreatment with fexofenadine (20 mg/kg, p.o.). The plasma clearance of fluvastatin was reduced by 44% in the presence of fexofenadine. The effect of fluvastatin on the pharmacokinetics of fexofenadine was also investigated in rats. The pretreatment with fluvastatin (5 or 10 mg/kg) decreased AUC and C-max of oral fexofenadine (10 mg/kg) by 47-53% and 28-60%, respectively, while it did not affect the intravenous pharmacokinetics of fexofenadine. Given that both fluvastatin and fexofenadine can interact with organic anion-transporting polypeptides (CATPs) expressed in intestine and liver, the present results suggest the potential drug interaction between fluvastatin and fexofenadine via the competition for the OATP-mediated cellular transport pathway during intestinal absorption and/or hepatic uptake of drugs. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:413 / 417
页数:5
相关论文
共 29 条
[1]  
APPEL S, 1995, AM J CARDIOL, V76, pA29
[2]   HMG-CoA reductase inhibitors and P-glycoprotein modulation [J].
Bogman, K ;
Peyer, AK ;
Török, M ;
Küsters, E ;
Drewe, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (06) :1183-1192
[3]  
Cvetkovic M, 1999, DRUG METAB DISPOS, V27, P866
[4]  
DAIN JG, 1993, DRUG METAB DISPOS, V21, P567
[5]  
DAVIGNON J, 1992, CAN J CARDIOL, V8, P843
[6]   Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine - A comparative review [J].
Devillier, Philippe ;
Roche, Nicolas ;
Faisy, Christophe .
CLINICAL PHARMACOKINETICS, 2008, 47 (04) :217-230
[7]   Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: Possible role of organic anion transporting polypeptides [J].
Dresser, GK ;
Kim, RB ;
Bailey, DG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (03) :170-177
[8]   Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine [J].
Dresser, GK ;
Bailey, DG ;
Leake, BF ;
Schwarz, UI ;
Dawson, PA ;
Freeman, DJ ;
Kim, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (01) :11-20
[9]  
Fischer V, 1999, DRUG METAB DISPOS, V27, P410
[10]   Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family [J].
Hagenbuch, B. ;
Gui, C. .
XENOBIOTICA, 2008, 38 (7-8) :778-801